Myelofibrosis (MF)
''Myelofibrosis is a serious bone marrow disorder that disrupts your body's normal production of blood cells. The result is extensive scarring in your bone marrow, leading to severe anemia, weakness, fatigue, and often, an enlarged spleen and liver.''
Definition by Mayo Clinic staff
VIDEOS
Understanding Myelofibrosis: Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
October 13, 2021, PeerView Oncology
Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis
April 9, 2020, OncLive
Overview of Myelofibrosis (Dr. Moshe Talpaz)
December 28, 2018, AJMCtv
Myelofibrosis for Patients
October 4, 2018, UT Health San Antonio MD Anderson Cancer Center
Myelofibrosis Targeted Treatment Approaches San Deigo 2015
September 16, 2015, MPN Advocacy and Education
Myelofibrosis Disease Overview and Treatment Options
July 1, 2015, The Leukemia & Lymphoma Society
Myelofibrosis Prognostic Scoring Systems: IPSS, DIPSS, DIPSS-Plus, MISPS, and GIPSS
May 15, 2015, ImedexCME
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
May 15, 2015, ImedexCME
Scott’s Myelofibrosis Story
May 14, 2015, Incyte: United in Support
Myelofibrosis Update 2015 - Mayo Clinic
December 16, 2014, Mayo Clinic
Myelofibrosis Update 2014 - Mayo Clinic
December 17, 2013, Mayo Clinic
New Mutation Identified in Primary Myelofibrosis Patients
December 10, 2013, Cancer Network
Understanding Myelofibrosis
August 30, 2013, Voices of MPN
Exciting Data on Developing Drugs for Myelofibrosis
July 6, 2013, Patient Power
Improving a Breakthrough: Combination Therapies with JAK Inhibitors
April 29, 2013, Patient Power
Myelofibrosis Emotional Support
March 11, 2013, CancerSupportComm
Myelofibrosis: Now and What's Coming for Treatment
January 22, 2013, Patient Power
Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations
December 19, 2012, Patient Power
Betty Brantley: A Newly Diagnosed Myelofibrosis Patient With High Hopes
December 13, 2012, Patient Power
The Significant Advancement in Myelofibrosis Symptom Management
November 15, 2012, Patient Power
Myelofibrosis and Bone Marrow Transplant - Mayo Clinic
July 19, 2012, Mayo Clinic
Myelofibrosis 2012 Update - Mayo Clinic
March 12, 2012, Mayo Clinic
Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis
March 2, 2012, OncLiveTV
Update on JAK Inhibitor — Spleen Volume Reduction and OS - Serge Verstovsek, MD, PhD.
January 27, 2012, OncUViewTV
Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
December 13, 2011, OncLiveTV
Myelofibrosis Research Update - Mayo Clinic
August 10. 2011, Mayo Clinic
Sonali Smith, MD: An Introduction to Myelofibrosis at ASCO 2011
July 17, 2011, vitaloptions
JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results
June 20, 2011, OncUViewTV
What Do Patients with Myelofibrosis Need to Know?
June 3, 2011, OncUViewTV
Myelofibrosis - Mayo Clinic
May 10. 2011, Mayo Clinic
Myelofibrosis in 2011 - MayoClinic
January 25. 2011, Mayo Clinic
CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.)
November 4, 2010, ymbiosciences
Myelofibrosis Treatment
September 15, 2010, Insidermedicine In Depth
New Drug Provides Rapid, Lasting Relief for Myelofibrosis Patients
September 15, 2010, mdandersonorg
Myelofibrosis Update - Dr. Ruben Mesa
May 17,2010, Mayo Clinic
Dr. Ruben Mesa discusses the symptoms, treatment and research being conducted for Myelofibrosis.
July 19, 2009, Mayo Clinic
Understanding Myelofibrosis: Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
October 13, 2021, PeerView Oncology
Dr. Rossetti on the Fast Track Designation of Momelotinib in Myelofibrosis
April 9, 2020, OncLive
Overview of Myelofibrosis (Dr. Moshe Talpaz)
December 28, 2018, AJMCtv
Myelofibrosis for Patients
October 4, 2018, UT Health San Antonio MD Anderson Cancer Center
Myelofibrosis Targeted Treatment Approaches San Deigo 2015
September 16, 2015, MPN Advocacy and Education
Myelofibrosis Disease Overview and Treatment Options
July 1, 2015, The Leukemia & Lymphoma Society
Myelofibrosis Prognostic Scoring Systems: IPSS, DIPSS, DIPSS-Plus, MISPS, and GIPSS
May 15, 2015, ImedexCME
Stem Cell Transplant for Myelofibrosis in the JAK2 Inhibitor Era
May 15, 2015, ImedexCME
Scott’s Myelofibrosis Story
May 14, 2015, Incyte: United in Support
Myelofibrosis Update 2015 - Mayo Clinic
December 16, 2014, Mayo Clinic
Myelofibrosis Update 2014 - Mayo Clinic
December 17, 2013, Mayo Clinic
New Mutation Identified in Primary Myelofibrosis Patients
December 10, 2013, Cancer Network
Understanding Myelofibrosis
August 30, 2013, Voices of MPN
Exciting Data on Developing Drugs for Myelofibrosis
July 6, 2013, Patient Power
Improving a Breakthrough: Combination Therapies with JAK Inhibitors
April 29, 2013, Patient Power
Myelofibrosis Emotional Support
March 11, 2013, CancerSupportComm
Myelofibrosis: Now and What's Coming for Treatment
January 22, 2013, Patient Power
Developments in Myelofibrosis: Ongoing Trials and the Significance of Mutations
December 19, 2012, Patient Power
Betty Brantley: A Newly Diagnosed Myelofibrosis Patient With High Hopes
December 13, 2012, Patient Power
The Significant Advancement in Myelofibrosis Symptom Management
November 15, 2012, Patient Power
Myelofibrosis and Bone Marrow Transplant - Mayo Clinic
July 19, 2012, Mayo Clinic
Myelofibrosis 2012 Update - Mayo Clinic
March 12, 2012, Mayo Clinic
Dr. Mesa Discusses JAK Inhibitors for Myelofibrosis
March 2, 2012, OncLiveTV
Update on JAK Inhibitor — Spleen Volume Reduction and OS - Serge Verstovsek, MD, PhD.
January 27, 2012, OncUViewTV
Dr. Hugh-Jones Discusses the JAK2 Inhibitor SAR302503
December 13, 2011, OncLiveTV
Myelofibrosis Research Update - Mayo Clinic
August 10. 2011, Mayo Clinic
Sonali Smith, MD: An Introduction to Myelofibrosis at ASCO 2011
July 17, 2011, vitaloptions
JAK Inhibitor Ruxolitinib COMFORT-II Trial Shows Positive Results
June 20, 2011, OncUViewTV
What Do Patients with Myelofibrosis Need to Know?
June 3, 2011, OncUViewTV
Myelofibrosis - Mayo Clinic
May 10. 2011, Mayo Clinic
Myelofibrosis in 2011 - MayoClinic
January 25. 2011, Mayo Clinic
CYT387: Potent Dual Inhibitor of JAK 1/2 in Phase I/II Clinical Development (YM BioSciences Inc.)
November 4, 2010, ymbiosciences
Myelofibrosis Treatment
September 15, 2010, Insidermedicine In Depth
New Drug Provides Rapid, Lasting Relief for Myelofibrosis Patients
September 15, 2010, mdandersonorg
Myelofibrosis Update - Dr. Ruben Mesa
May 17,2010, Mayo Clinic
Dr. Ruben Mesa discusses the symptoms, treatment and research being conducted for Myelofibrosis.
July 19, 2009, Mayo Clinic
ARTICLES
FDA Approves Jakafi
November 16, 2011, Drugs.com
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
September 16, 2010, The New England Journal of Medicine
FDA Approves Jakafi
November 16, 2011, Drugs.com
Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
September 16, 2010, The New England Journal of Medicine